Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
J.B.CHEMICALS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
J.B.CHEMICALS Mar-23 |
ADCOCK INGRAM Jun-14 |
J.B.CHEMICALS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,150 | 314 | - | |
Low | Rs | 1,339 | 226 | - | |
Sales per share (Unadj.) | Rs | 407.0 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 53.0 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 67.8 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 8.88 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 304.8 | 73.3 | - | |
Shares outstanding (eoy) | m | 77.38 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.3 | 2.9 | 148.1% | |
Avg P/E ratio | x | 32.9 | -11.5 | -286.7% | |
P/CF ratio (eoy) | x | 25.7 | -13.9 | -185.8% | |
Price / Book Value ratio | x | 5.7 | 3.7 | 155.2% | |
Dividend payout | % | 16.7 | 0 | - | |
Avg Mkt Cap | Rs m | 134,983 | 45,603 | 296.0% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 5,435 | 2,862 | 189.9% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 31,493 | 15,761 | 199.8% | |
Other income | Rs m | 99 | 110 | 90.1% | |
Total revenues | Rs m | 31,592 | 15,872 | 199.0% | |
Gross profit | Rs m | 6,958 | -2,731 | -254.7% | |
Depreciation | Rs m | 1,144 | 680 | 168.2% | |
Interest | Rs m | 361 | 427 | 84.4% | |
Profit before tax | Rs m | 5,552 | -3,728 | -148.9% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,452 | 233 | 623.4% | |
Profit after tax | Rs m | 4,100 | -3,971 | -103.2% | |
Gross profit margin | % | 22.1 | -17.3 | -127.5% | |
Effective tax rate | % | 26.2 | -6.2 | -418.6% | |
Net profit margin | % | 13.0 | -25.2 | -51.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,993 | 11,544 | 138.5% | |
Current liabilities | Rs m | 6,257 | 6,495 | 96.3% | |
Net working cap to sales | % | 30.9 | 32.0 | 96.5% | |
Current ratio | x | 2.6 | 1.8 | 143.8% | |
Inventory Days | Days | 85 | 111 | 76.8% | |
Debtors Days | Days | 667 | 124 | 538.4% | |
Net fixed assets | Rs m | 24,988 | 6,729 | 371.4% | |
Share capital | Rs m | 155 | 73 | 211.5% | |
Net worth | Rs m | 23,587 | 12,371 | 190.7% | |
Long term debt | Rs m | 3,832 | 4,347 | 88.2% | |
Total assets | Rs m | 40,981 | 23,369 | 175.4% | |
Interest coverage | x | 16.4 | -7.7 | -212.1% | |
Debt to equity ratio | x | 0.2 | 0.4 | 46.2% | |
Sales to assets ratio | x | 0.8 | 0.7 | 113.9% | |
Return on assets | % | 10.9 | -15.2 | -71.8% | |
Return on equity | % | 17.4 | -32.1 | -54.1% | |
Return on capital | % | 21.6 | -19.8 | -108.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,256 | 1,345 | 465.0% | |
From Investments | Rs m | -9,618 | -413 | 2,328.3% | |
From Financial Activity | Rs m | 3,565 | 3,945 | 90.4% | |
Net Cashflow | Rs m | 204 | 4,878 | 4.2% |
Compare J.B.CHEMICALS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare J.B.CHEMICALS With: UNICHEM LAB SHUKRA PHARMA LYKA LABS SANDU PHARMA AARTI DRUGS
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.